Show
Sort by
-
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
-
- Journal Article
- A1
- open access
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
-
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials
-
The NF1 hotspot in acute myeloid leukemia : what’s in a name?
-
Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia
-
Leptin receptor antagonism of iNKT cell function : a novel strategy to combat multiple myeloma
-
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
-
Long noncoding RNA signatures define oncogenic subtypes in T-cell acute lymphoblastic leukemia
-
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951